Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TS03 Inc Trust Units TSTIF



GREY:TSTIF - Post by User

Post by echo2on Sep 07, 2017 7:23pm
268 Views
Post# 26669309

News Update in Full

News Update in Full

A good start to news flow!

Vancouver General's experience with the VP4 sterilizing duodenoscopes will help to further validate this ground-breaking technology and serve as an example to others who want to provide the best state-of-the-art standard of care for their patients undergoing ERCP. And, I look forward to the data they will no doubt accumulate and publish in the near future on their experience confirming efficacy of the VP4 and its cost efficiencies.

It is also noteworthy that the regulators, (presumably FDA), did not note any problems at TSO3's production facility. I am sure the open exchange of information with regulators will serve TSO3 very well as they design and execute a new production facility in the US in order to meet anticipated demand!

And, finally, Getinge's sales and service team has had extensive proper instruction and been brought up to speed with this exciting new technology. (My only complaint is that Getinge should have had their people trained like this a year ago! Are they only now interested in taking advantage of TSO3's expert training and personnel since they are now on the verge of having the financial ability to make a run at buying TOS?)



TSO3 Provides an Update on Recent Activities 

Thursday, September 7, 2017

 

Quebec City, Canada and Myrtle Beach, United States, September 7, 2017 – TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that a major hospital in Canada has initiated terminal sterilization of duodenoscopes with the Company’s STERIZONE® VP4 Sterilizer.  Additionally, the Company has successfully completed both a Quality System compliance inspection by US regulators and four weeks of comprehensive sales and marketing training with personnel from its exclusive distribution partner, the Getinge Group.  

The Company announced that the second largest hospital in Canada has completed the installation of multiple STERIZONE® VP4 Sterilizers and is now using these sterilizers to terminally process duodenoscopes used on patients undergoing endoscopic retrograde cholangio-pancreatography (ERCP) procedures.  The Company’s STERIZONE® VP4 Sterilizer is the only validated system cleared for the terminal sterilization of duodenoscopes (US claim pending clearance) as well as other complex multi-channeled flexible endoscopes such as colonoscopes and gastroscopes.  

Terminal sterilization of duodenoscopes represents an entirely new level of patient protection as compared to the less robust disinfecting systems in use today.   Disinfecting processes are under increasing public and regulatory scrutiny given a number of documented cases of duodenoscope-related patient-to-patient transfer of antibiotic resistant micro-organisms, some of which have led to patient deaths. 

For the first time in history, an industry leading medical facility is terminally sterilizing duodenoscopes using a validated process, a major advancement in healthcare and patient safety, and they are using TSOtechnology,” stated R.M. (Ric) Rumble, TSO3’s President and CEO.  “Terminal sterilization is now an option for healthcare facilities who are concerned about scope-related patient-to-patient transfer of contaminants.  Ineffective endoscope reprocessing is a pressing global healthcare issue and we believe sterilization is a major part of the solution.  TSO3 is now working with additional leading healthcare facilities in Canada, in the United States and in Europe on STERIZONE® VP4 Sterilizer installations for the specific purpose of terminally sterilizing duodenoscopes and other endoscopes.” 

TSO3 also announced the successful completion of a routine Quality System compliance inspection by US regulators.  The Company passed the inspection without any reportable findings – which is considerable given the rapid expansion of the Company.  The Company has and continues to follow a continuous improvement based regulatory compliance program which was commended by the regulators.  

Lastly, the Company announced the completion of a comprehensive four week training program for customer facing representatives from its exclusive distributor, the Getinge Group.  This training was conducted by in-house staff and satisfied medical facility end users.  It covered selling and marketing material, technical information, clinical input, and customer Q&A preparation.  

About the STERIZONE® VP4 Sterilizer

The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines. 

The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process. 

The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb.  The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).  More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at https://www.tso3.com/en/products/sterizone-vp4/

 

<< Previous
Bullboard Posts
Next >>